Article Text

Download PDFPDF

Cervus and cucumis peptides ameliorates bone erosion in experimental arthritis by inhibiting osteoclastogenesis
  1. Ze-Min Lin1,
  2. Yu-Ting Liu1,2,
  3. Yan-Sheng Xu3,
  4. Xiao-Qian Yang1,
  5. Feng-Hua Zhu1,
  6. Wei Tang1,2,
  7. Shi-Jun He1 and
  8. Jian-Ping Zuo1,2,3
  1. 1Laboratory of Immunopharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica Chinese Academy of Sciences, Shanghai, China
  2. 2University of Chinese Academy of Sciences, Beijing, China
  3. 3Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  1. Correspondence to Dr Jian-Ping Zuo; jpzuo{at}simm.ac.cn; Dr Shi-Jun He; heshijun{at}simm.ac.cn

Abstract

Objective Rheumatoid arthritis is an autoimmune disease characterised by inflammation and bone loss, leading to joint destruction and deformity. The cervus and cucumis polypeptide (CCP) injection, one of the traditional Chinese medicine injections combined extracts from deer horn and sweet melon seeds, is widely used to treat arthritis and bone fracture in China. The present study investigated the therapeutic efficacy and mechanism of CCP on pathological immune cells and bone homoeostasis in rodent experimental arthritis.

Methods The effects of CCP (4 mg/kg and 2 mg/kg) on clinical arthritis symptoms, bone erosion, proinflammatory cytokines and pathological immune cells induced by complete Freund’s adjuvant was evaluated in male Sprague-Dawley rats. The impacts of CCP (2 mg/kg) on joint erythema and swelling, production of pathogenic antibodies and the proportion of inflammatory cells were assessed in collagen-induced arthritis (CIA) in DBA/1J mice. Regulation of osteoclastogenesis by CCP was observed in the murine macrophage-like RAW264.7 cells treated with receptor activator of nuclear factor-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF).

Results CCP administration significantly prevented disease progression in both adjuvant-induced arthritis (AIA) rats and CIA mice. The therapeutic benefits were accompanied by reduction of paw oedema, reversed bone destruction, decreased pathological changes and osteoclast numbers in joints in AIA rats, as well as attenuated clinical manifestation and autoantibodies production in CIA mice. Meanwhile, in vitro supplemented of CCP concentration dependently inhibited RANKL/M-CSF-induced osteoclast differentiation, without showing cytotoxicity in RAW264.7 cells. Further, the presence of CCP dampened the augmented downstream signalling transduction as well as activation of osteoclast-specific genes and transcription factors induced by RANKL/M-CSF in RAW264.7 cells.

Conclusion Our study suggested that the therapeutic effects of CCP in experimental arthritis could be attributed to its intervention on RANKL-induced osteoclastogenesis signalling pathway in osteoclast precursor cells.

  • cervus and cucumis peptides
  • rheumatoid arthritis
  • adjuvant-induced arthritis
  • collagen-induced arthritis
  • osteoclastogenesis

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Z-ML and Y-TL are joint first authors.

  • Z-ML and Y-TL contributed equally.

  • Contributors Study concept and design: JZ, SH, ZL and YL; Acquisition of data: ZL, YL, SH, YX, XY, FZ and WT; Anslysis and inerpretation of the data: SH, ZL and YL; Write the main manuscript text: JZ, SH and ZL. All authors approved the final version to be published.

  • Funding This work was supported by the 'Personalized Medicines—Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences (grant number: XDA12020107); The National Basic Research Program of China (973 Program) (grant number: 2014CB541906) and the National Nature Science foundation of China (grant number: 81402939)

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval The animal experiments were carried out in strict accordance with the institutional ethical guidelines on animal care and were approved by the Institute Animal Care and Use Committee (IACUC) at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (IACUC protocol #2015–04-ZJP-39 for SD rats, #2016–11-ZJP-59 for DBA/1J mice).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.